Prolactin and placental hormone levels during pregnancy in prolactinomas.
Prolactin (PRL) and the placental hormones, estradiol (E2), estriol (E3), progesterone (PG), chorionic gonadotropin (HCG), and placental lactogen (HPL) were serially measured throughout pregnancy and early postpartum in three patients with prolactinomas in whom pregnancy was achieved by one of the three modalities of treatment: bromocriptine administration (patient I), irradiation of the pituitary (patient II), and human gonadotropin administration after excision of the adenoma (patient III). It was found that PRL in patient I reached the high pretreatment levels in the 2nd month of pregnancy and increased to further abnormal concentrations in the last 2 months, but fell at the onset of labor 1 week after an episode of severe headache. The PRL changes in this patient were attributed successively to tumor expansion and apoplexy. In patient II PRL decreased after irradiation, but was not normalized. During pregnancy it remained moderately increased presenting minor fluctuations. The third patient with postoperative GH and TSH pituitary insufficiency had low pretreatment PRL levels which remained practically unchanged throughout pregnancy. The two last patients gave birth to identical twins. The placental hormones were found normal in all three patients but E2 and PG were relatively increased during the last weeks of pregnancy in the twin pregnancies. Amniotic fluid and umbilical cord PRL and E2 concentrations were normal. The patients presented agalactia and suckling did not induce a PRL increase. We conclude that a) serial PRL measurements during pregnancy reflect the changes occurring in the prolactinomas and are essential in monitoring the patients bearing these tumors; b) maternal hyperprolactinemia or failure of PRL to increase during pregnancy do not influence either the secretion of placental hormones or PRL concentration in amniotic fluid and the newborn; and c) hyperprolactinemia during pregnancy is of maternal pituitary origin.
D000236:Adenoma / Q000378:metabolism / Q000628:therapy*; D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D001971:Bromocriptine / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000378:metabolism; D005260:Female; D012739:Gonadal Steroid Hormones / Q000378:metabolism; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010910:Pituitary Irradiation; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000628:therapy*; D010926:Placental Hormones / Q000378:metabolism*; D010928:Placental Lactogen / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism / Q000628:therapy*; D011388:Prolactin / Q000378:metabolism*; D014470:Umbilical Cord / Q000378:metabolism
D006063:Chorionic Gonadotropin; D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D010926:Placental Hormones; D001971:Bromocriptine; D011388:Prolactin; D010928:Placental Lactogen